Appendix Table A2.
Artifact Confirmation in the MBP and LOPAC PXR Assays
| Sample ID | Name | Channel (nm emission) | Structure | MBP curve class | LOPAC run 1, 2, and 3 curve classes |
|---|---|---|---|---|---|
| NCGC00025016-02 | Quercetin | 495 |  |
-2b | -2b, −3, −3 |
| NCGC00025134-02 | GW5074 | 495 |  |
-2b | -2b, −3, −3 |
| NCGC00025170-02 | SU 4312 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00025186-02 | SP 600125 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00025211-02 | NSC 95397 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00091540-02 | Emodin | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00093542-01 | 5-(N,N-Dimethyl) amiloride hydrochloride | 495 |  |
-2b | -2b, −3, −3 |
| NCGC00093577-01 | 4-Amino-1,8-naphthalimide | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00093601-01 | 5-(N,N-Hexamethylene) amiloride | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00093644-01 | Amsacrine hydrochloride | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00093830-01 | Dephostatin | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00093870-01 | R(-)-2,10,11-Trihydroxy-N-propylnoraporphine hydrobromide | 495 |  |
-2b | -2b, −3, −2ba |
| NCGC00093966-01 | BU99006 | 495 |  |
-2b | -2b, −2b, −3 |
| NCGC00093976-01 | Idarubicin | 495 |  |
-2a | -2a, −2a, −2a |
| NCGC00094000-01 | 6-Hydroxy-dl-DOPA | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094031-01 | Ro 90-7501 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094083-01 | Myricetin | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094116-01 | Mitoxantrone | 495 |  |
-1a | -2a, −2a, −2a |
| NCGC00094188-01 | Methysergide maleate | 495 |  |
-2b | -3, −3, −2b |
| NCGC00094195-01 | Me-3,4-dephostatin | 495 |  |
-2a | -2a, −2a, −2a |
| NCGC00094223-01 | NBQX disodium | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094243-01 | PPNDS tetrasodium | 495 |  |
-2ba | -2a, −2a, −2a |
| NCGC00094244-01 | SU 9516 | 495 |  |
-2a | -2a, −2a, −2a |
| NCGC00094273-01 | Protoporphyrin IX disodium | 495 |  |
-2ba | -2b, −2b, −2b |
| NCGC00094309-01 | IC 261 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094336-01 | Reactive Blue 2 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094406-01 | Tyrphostin AG 112 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094427-01 | Tyrphostin AG 34 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094443-01 | Tyrphostin 25 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094466-01 | Tyrphostin 47 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094473-01 | Tyrphostin 51 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094491-01 | I-OMe-Tyrphostin AG 538 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094499-01 | Tyrphostin AG 538 | 495 |  |
-2b | -2b, −2b, −2b |
| NCGC00094505-01 | WB 64 | 495 |  |
-2a | -2b, −2b, −2b |
| NCGC00093577-01b | 4-Amino-1,8-naphthalimide | 520 |  |
1a | 2a, 2a, 2a |
| NCGC00093754-01 | 7-Chloro-4-hydroxy-2-phenyl-1,8-naphthyridine | 520 |  |
3 | 3, 3, 3 |
DOPA, 3,4-dihydroxy-l-phenylalanine; NBQX, 1,2,3,4-tetrahydro-6-nitro-2,3-dioxo-benzo[f]quinoxaline-7-sulfonamide; Abs, absolute flag indicating that the exact stereoisomer is as drawn; PPNDS, pyridoxal-5′-phosphate-6-(2′-naphthylazo-6′-nitro-4′,8′-disulfonate.
a
These CRCs had poor r2 values.
b
Fluorescent compound in 480 nmexcitaton/540 nmemission region based on previous spectroscopic data (PubChem assay identifier 591).